MedTrace Logo

Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection Associated Chronic Conditions

NCT06257420 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2026-05-18

No results posted yet for this study

Summary

The goal of this observational study is to assess the clinical response and the effect of autophagy function in patients before, during and throughout oral low dose sirolimus (rapamycin) therapy. The main questions this study aims to answer are:

* Does rapamycin reduce the overall symptom burden in this patient population and does it improve the quality of life?
* Does rapamycin change mTOR driven autophagy deficits observed in a subset of patients?

Participants will be asked to complete a series of questionnaires and quality of life instruments before starting rapamycin therapy prescribed by their physician and throughout their course of treatment. Study blood samples will be collected before starting therapy and throughout the course of treatment to assess serological markers of autophagy function.

Conditions

  • Myalgic Encephalomyelitis
  • Long-COVID

Interventions

DRUG

Rapamycin

Once weekly oral rapamycin

Sponsors & Collaborators

  • Center For Complex Diseases-Seattle, WA

    collaborator UNKNOWN

  • Sierra Internal Medicine, Incline Village, NV

    collaborator UNKNOWN

  • Center for Complex Diseases- Palo Alto, CA

    collaborator UNKNOWN

  • Simmaron Research Inc. R&D Lab, University of Wisconsin, Milwaukee (UWM)

    collaborator UNKNOWN

  • Bateman Horne Center, Salt Lake City, UT

    collaborator UNKNOWN

  • Mayo Clinic

    collaborator OTHER

  • Simmaron Research Inc.

    lead OTHER

Principal Investigators

  • Gunnar Gottschalk, PhD · Simmaron Research Inc.

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-11
Primary Completion
2027-07-01
Completion
2027-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06257420 on ClinicalTrials.gov